Undoubtedly, the Snap, Inc. (SNAP) IPO has caught the attention of the investment community this morning and throughout the day today.  The tech company known most for its mobile social media application finally went public amidst much speculation and has managed to hit highs of $25.88.  Some speculate that it will fail and other are holding much higher expectations but this being just the first day, certainly it’s been this speculation that has helped to ignite attention in the market for Snap, Inc.

Outside of this event, many penny stocks have also been trending on higher attention today. Amicus Therapeutics (FOLD) has seen its fourth consecutive day of positive price movement. The company recently announced its full year 2016 financial results while also giving a corporate update to shareholders. The company is expecting a favorable year in 2017 with increases in patient enrollment throughout their programs being deployed across the globe. This week the share price has jumped from $5.94 to highs of $8.10 on Thursday morning.

Shares of Peregrine Pharmaceuticals (PPHM) have also seen an increase in price over the last month. In fact, since the beginning of the year, shares have climbed as high as $0.66 from $0.31 where the stock opened at on January 3. The company recently published positive proof-of-concept data for a new exosome-based cancer detection platform and since then the company’s market cap has managed to consistently increase during the weeks to follow.

Vitality Biopharma (VBIO) has seen its first green day in weeks on Thursday. The stock has been battling downward pressure since late February and after hitting lows of $1.56 on Wednesday, the stock has managed to reverse in price movement.  In fact on Thursday, shares of VBIO hit highs of $2.15 to mark a rebound of as much as 38% from those previous lows. The company made the announcement that it has created a library of proprietary glycosides of THC. The company is developing these compounds as pharmaceuticals that may allow for site-specific targeting of the THC in different tissues of the body in order to reply the therapeutic effects to combat pain and inflammation.  Director of R & D for Vitality, Dr. Brandon Zipp said, “This new drug opens up novel opportunities for treatment of pain and inflammation. We can now exploit the cannabinoid receptor system without systemic THC that compromises cognitive function.”